Long-term opioid use often begins with the treatment of acute pain with opioids (Edlund et al., 2014) . In an attempt to reduce the postoperative use of opioids for acute pain, perioperative ketamine treatment may be of importance. Ketamine acts as a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist on the NMDA receptors in the brain and the spinal cord (Bell, Dahl, Moore, & Kalso, 2005; Mao, 2002; Peltoniemi, Hagelberg, Olkkola, & Saari, 2016) . We therefore conducted a randomized controlled trial on opioid-dependent patients hypothesizing that intraoperative S-ketamine has immediate and long-term effects on analgesic consumption, and pain after spinal fusion surgery. The results from the early postoperative phase (0-24 hr) and 6-month follow-up have been presented elsewhere (Nielsen et al., 2017) . We now report the 1-year follow-up results.
| METHODS
This is the 1-year follow-up of a single-centre, prospective, randomized and blinded trial exploring the effects of intraoperative S-ketamine on opioid consumption and pain after spinal fusion surgery in opioid-dependent patients. The trial was performed at Department of Neuroanesthesiology, Rigshospitalet-Glostrup, Copenhagen University Hospital, Denmark from 19 May 2014 to 2 October 2015. The 1-year follow-up period was from 19 May 2015 to 1 November 2016. The trial fulfilled Good Clinical Practice guidelines, the Helsinki Declarations, and the Consolidated Standards of Reporting Clinical Trials statement (CONSORT; Moher, Schulz, & Altman, 2001) . It was approved by the Regional Research Ethics Committee and all patients gave written informed consent before participating. The trial is registered at Clinicaltrials.gov (NCT02085577).
One hundred and forty-seven adult patients undergoing lumbar fusion surgery were included in the final analyses (Nielsen et al., 2017) . Trial inclusion criteria included chronic back pain >3 months preoperatively, daily use of opioids for back pain >6 weeks preoperatively (morphine, oxycodone, tramadol, buprenorphine, fentanyl or ketobemidone). Further inclusion and exclusion criteria were previously reported (Nielsen et al., 2017) .
Patients were randomly assigned to perioperative S-ketamine bolus 0.5 mg/kg followed by infusion of S-ketamine 0.25 mg kg −1 hr −1 until end of surgery, or placebo.
The intervention was blinded to patients, investigators and all staff. The pharmacy generated randomization code was disclosed after 6-month follow-up for statistical analyses but prior to 1-year follow-up. Patients remained blinded at 1-year follow-up. The primary outcome: Total PCA morphine 0-24 hr postoperatively, and secondary outcomes: Acute pain, adverse events and 6-month follow-up are previously published (Nielsen et al., 2017) . In brief, the main results were that morphine consumption, both perioperatively and at 6 months after surgery, was reduced in the ketamine group compared with the placebo group (Nielsen et al., 2017) .
The 1-year follow-up is reported here and includes five written postal questionnaires all validated for spine surgery patients: (a) The Dane Spine Questionnaire including patient-reported analgesics, (b) The Oswestry Low Back Pain Questionnaire (Fairbank & Pynsent, 2000) , (c) EuroQol 5D-3L, (d) The Douleur Neuropathique 4, and (e) Short form 36 survey (SF-36). If patients had not returned the questionnaires after three weeks, they received one written reminder.
We used SPSS ver. 22.0 for Windows (SPSS, Chicago, IL, USA) for statistical analyses. Variables were tested for normal distribution and the Students t test and Mann-Whitney U test were applied as appropriate. Categorical data were analysed using chi-squared test or Fisher's exact test. p Values < 0.05 were considered statistically significant. Outcomes measured repeatedly were Bonferroni corrected.
| RESULTS
One hundred and forty-seven patients received the 1-year follow-up questionnaires. Reply rates were as follows: Ketamine group 47/74 (64%) patients, placebo group 51/73 (70%) patients, with an overall response rate of 67% (Figure 1 ). For patient characteristics see Table 1 . Both trial groups were comparable at baseline (Table 1) . Responders and non-responders were similar regarding age, height, weight, preoperative pain, and pain and morphine consumption 0-24 hr after surgery.
Fewer patients in the ketamine group reported a daily use of analgesics one year postoperatively compared to the placebo group, 42% (95% CI 23-61) versus 74% (95% CI 58-87), respectively, (p = 0.04; Table 2 ). Daily use of morphine equivalents was lower in the ketamine group versus the placebo group: 0 (0-20) mg versus 20 (0-62) mg, (p = 0.02). For details see Table 2 .
One year after surgery, visual analogue scale (VAS) pain intensity was lower in the ketamine group versus the placebo group, as regards mobilization pain, 31 (13-63) versus 57 (30-79) mm, respectively, median difference 16 mm (95% CI −30 to −2), (p = 0.02); (Table 2 ). Figure 2 demonstrates the difference in pain reduction from before surgery to one year after surgery between groups. According to the DN4, neuropathic pain did not differ between groups (Table 3) .
Labour market attachment (working, still on sick leave, on disability pension or retired) demonstrated that 43% (95% CI 26-60) of patients in the ketamine group versus 28% (95% CI 15-41) in the placebo group was working, (p = 0.02; Table 2 ).
Results from Oswestry Low Back Pain Questionnaire are summarized as an Index Score 0-100, with 0-20 being minimal disability and 81-100 being patients who are bed-bound. Patients in the ketamine group had a lower Oswestry disability index score of 26 (10-36) versus 36 (24-51), p = 0.04 (Table 3 ). The EQ-5D-3L questionnaire is summarized in Table 3 . The category pain/discomfort differed significantly between groups, but not mobility, self-care, activities and anxiety/depression categories. The SF-36 did not differ between groups (Table 3) .
| DISCUSSION AND CONCLUSIONS
In this trial, we found that patients who received S-ketamine during spine surgery, reported reduced opioid consumption and pain one year after surgery as compared to patients who received placebo. Further, labour market attachment was higher for patients in the ketamine group.
A previous trial explored the effect of intraoperative racemic ketamine infusion in a similar patient population with opioid dependency and chronic pain (Loftus et al., 2010) . The results showed reduced pain and opioid consumption immediately and 6 weeks after surgery for the ketamine group. Pain levels 6 weeks after surgery, however, may not be descriptive for a chronic state, as chronic and persistent Seventy-five per cent of the patients in our 1-year follow-up also responded to the 6-month follow-up. This difference may explain some differences in the 6-month and 1-year results (Nielsen et al., 2017) . The between groups difference for labour market attachment one year after surgery cannot be compared to the preoperative work status, as these data were unavailable. However, our patient-groups were well matched for other preoperative characteristics: Pain, opioid consumption and psychological factors. Postoperatively the patients in both groups had comparable acute pain levels, but the postoperative 24-hr morphine consumption was significantly reduced in the ketamine group compared with the placebo group. Whether the observed long-term effect of ketamine is due to a reduction in acute opioid consumption, attenuation of central sensitization and hyperalgesia, or perhaps a psychological effect with a secondary effect on pain, remains unsettled. In crude numbers, there was a difference in daily opioid consumption both at 6-month and 1-year, however, only significant at 1-year. The opioid consumption was generally low in both groups, challenging the ability to detect a difference.
Our results are limited by the reduced response rate of 67% at the 1-year follow-up. Strength and weaknesses of the original trial design are previously discussed (Nielsen et al., 2017) .
In conclusion, intraoperative S-ketamine may reduce analgesic use and pain one year after spine surgery and improve 
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